4D Molecular Therapeutics tumbles following mid-stage clinical study results - Investing.com
4D Molecular Therapeutics, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $9.71
+18% in 7d after detection
Post-detection moves
1h
—
1d
+0.8%
3d
+2.3%
7d
+18%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS